Washington, DC 11/15/10; Washington, DC 11/19/10—DNA sequencer firm Helicos BioSciences has been delisted from the NASDAQ stock exchange after withdrawing its appeal (see IBO 10/15/10). The stock now trades on the OTC Markets. Last month, the company received a delisting determination letter from NASDAQ due to its failure to comply with the minimum bid price requirement. Helicos had failed to post a closing bid price of more than one dollar for 30 consecutive business days. In an SEC filing, Helicos stated that it was unlikely to meet the requirement due to “the state of its finances and near-term business prospects.” On November 19, Helicos announced that it had entered into an insider bridge loan facility with Atlas Venture and Flagship Ventures due to a lack of prospects of securing long-term financing from outside investors. The agreement provides for an aggregate committed amount of $2 million.